Facebook Linkedin RSS Twitter Youtube
Home 2024

Eisai Pharmaceuticals

Alzheimer’s Drug Shows Slower Cognitive Decline in Lower Tau Patients
Drug Discovery

Alzheimer’s Drug Shows Slower Cognitive Decline in Lower Tau Patients

StockWatch: Athira Pays Price as Alzheimer’s Candidate Fails Trial
Drug Discovery

StockWatch: Athira Pays Price as Alzheimer’s Candidate Fails Trial

StockWatch: Cognition Stays the Course as Shares Plunge on Alzheimer’s Data
Drug Discovery

StockWatch: Cognition Stays the Course as Shares Plunge on Alzheimer’s Data

FDA Approves Lilly’s Amyloid-Targeting Kisunla for Early Alzheimer’s
Drug Discovery

FDA Approves Lilly’s Amyloid-Targeting Kisunla for Early Alzheimer’s

Alzheimer’s Drug Developer Alzheon Closes $100M Series E Financing
Drug Discovery

Alzheimer’s Drug Developer Alzheon Closes $100M Series E Financing

AI, Cell/Gene Therapy, Precision Medicine Drive Bullish Biotech Investment
Artificial Intelligence

AI, Cell/Gene Therapy, Precision Medicine Drive Bullish Biotech Investment

Carpenter Builds a Broad Cell Imaging Consortium to Accelerate Drug Discovery and Development
Drug Discovery

Carpenter Builds a Broad Cell Imaging Consortium to Accelerate Drug Discovery and Development

ImmunoGen Shares Plunge after Phase III Failure of Lead ADC in Ovarian Cancer
Cancer

ImmunoGen Shares Plunge after Phase III Failure of Lead ADC in Ovarian Cancer

“Some Hope”: Biogen, Eisai Release Positive Phase II Results for Alzheimer’s Candidate
Industry News

“Some Hope”: Biogen, Eisai Release Positive Phase II Results for Alzheimer’s Candidate

Dr. Reddy’s Buys Ex-Asia Rights to Eisai Cancer Candidate E7777
Cancer

Dr. Reddy’s Buys Ex-Asia Rights to Eisai Cancer Candidate E7777

12Page 1 of 2
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.